Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Account Payables: 2021-2025

Historic Change in Account Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $335,924.

  • SAB Biotherapeutics' Change in Account Payables rose 149.54% to $335,924 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 669.77%. This contributed to the annual value of $923,323 for FY2024, which is 134.18% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Change in Account Payables of $335,924 as of Q3 2025, which was up 143.12% from $138,171 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Change in Account Payables ranged from a high of $2.0 million in Q2 2021 and a low of -$3.8 million during Q1 2021.
  • Over the past 3 years, SAB Biotherapeutics' median Change in Account Payables value was $134,618 (recorded in 2024), while the average stood at -$56,376.
  • In the last 5 years, SAB Biotherapeutics' Change in Account Payables slumped by 633.56% in 2022 and then soared by 658.16% in 2024.
  • SAB Biotherapeutics' Change in Account Payables (Quarterly) stood at $338,327 in 2021, then slumped by 633.56% to -$1.8 million in 2022, then soared by 94.14% to -$105,773 in 2023, then skyrocketed by 658.16% to $590,385 in 2024, then soared by 149.54% to $335,924 in 2025.
  • Its Change in Account Payables stands at $335,924 for Q3 2025, versus $138,171 for Q2 2025 and $684,171 for Q1 2025.